Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phas... ( Central Texas man receives groundbrea...)

HOME >> BIOLOGY >> TECHNOLOGY

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial

Date:3/31/2009

Central Texas man receives groundbreaking therapy days after heart attack

AUSTIN, Texas, March 31 /PRNewswire/ -- On March 30, the Heart Hospital of Austin treated the first patient in the world enrolled in a groundbreaking Phase II study designed to test the effectiveness and safety of administering adult stem cells intravenously to repair damaged heart tissue after a heart attack.

Dr. Roger Gammon, a cardiologist with Austin Heart cardiology group treated a 58-year-old Central Texas man with the experimental adult stem cell treatment, just days after his first heart attack.

"We are excited to be the first to treat a patient in this groundbreaking study and to lead the way in this important research," states Dr. Gammon "Austin Heart and the Heart Hospital of Austin were selected because of their proven history of excellence in cardiovascular research and strong performance in the earlier Phase I trial," Gammon adds.

Prochymal(R) is being evaluated for its ability to treat heart damage caused by a heart attack. The active ingredient in the new treatment is adult Mesenchymal Stem Cells (MSCs). The cells in the drug are from normal, healthy adult volunteer donors and are not from a fetus, embryo or animal. MSCs have the ability to develop into other types of cells and generate new tissue, including heart muscle. Prochymal(R) is a product of Osiris Therapeutics, Inc.

"There's a lot of enthusiasm in the cardiovascular community about the potential of stem cell therapies for treating heart disease. Earlier studies have established confidence in the safety of the therapy, but more research is needed to study its effectiveness," states Gammon.

In this prospective, double-blind, placebo-controlled Phase II study, Heart Hospital of Austin and Austin Heart researchers will study patients to determine the effectiveness and safety of Prochymal(R) fo
'/>"/>

SOURCE Heart Hospital of Austin
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2
Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. ATS Medical Expands Open Pivot Heart Valve Offerings
3. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
4. Signalifes Dr. Harmison Launches Award-Winning Ambulatory Heart Monitor
5. Cleveland Clinic-Led Research Uncovers New Mechanism That Heightens Risk of Heart Disease
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Panel to Discuss the Far-Ranging Effects and Consequences of Heart Disease, Which is the Leading Killer in Both Men and Women in the United States
8. Cheetah Medicals NICOM Non-Invasive Cardiac Output Monitor Featured in a Presentation at the Heart Failure Society of America (HFSA) Annual Meeting
9. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
10. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
11. CV Therapeutics Announces Presentations at American Heart Association Scientific Sessions 2007

Post Your Comments:

(Date:12/2/2009)...Dec. 2 According to the National I...ericans diagnosed with diabetes already have some ...hy, damage to the retina caused by leaky blood ves... diabetes and is one of the most feared diabetic c...tients who,ve had diabetes for 10 years or more wi...

(Date:12/1/2009)...Dec. 1 Reportlinker.com announces ...its catalogue: ,, Chromium - Global Market Tr.../Chromium---Global-Market-Trends.html ,, World...y stainless steel, while growth in aerospace and i...r growth of chromium metal. Environmental constrai...

(Date:12/1/2009)... Dec. 1 Harvest Technologies Corp....rom the company sponsored 60-patient clinical tria...hennai, India using the company,s BMAC System to t...mb Ischemia (CLI). Sri Ramachandra Medical Center ...itution based in Chennai, India and one of the lar...

(Date:12/1/2009)...ec. 1 /PRNewswire-Asia/ -- Shanghai ChemPartner, a...g China-based Contract Research,Organization (CRO)...tte,Technology Fast 50 China, ranking 3rd on the l...China. The award is a testament to ChemPartner,s o...2008. , The results of the 2009 Deloitte ...

[0] Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy [0] Reportlinker Adds Chromium - Global Market Trends [0] Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia [0] Shanghai ChemPartner Ranks 3rd among 2009 Deloitte Technology Fast 50 China Winning Companies

... for Neurological Diseases and,Disorders, OLDSMAR...International,Inc. (OTC Bulletin Board: CCEL) ("Cr... most established family cord blood banks, today a...elopment agreement with Saneron CCEL,Therapeutics,...estone in,efforts to develop promising regenerativ...

...E PARK, N.C., Jan. 29 ,Merial Limited and Chimerix...reement under which Merial will screen a Chimerix ...er the terms of this agreement, Merial has an,opti...identified for,possible animal health use., "This...pportunity to,further expand our ability to identi...

... end; no equity financings expected in 2008, - Si...ams to continue in,2008; latest data for all progr...Expansion of research and development investment i... targets beyond lysosomal diseases in 2008, CRANB...FOLD ), a biopharmaceutical company developing sma...

Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements

(Date:12/2/2009)...igher IQ and are more likely to go on to universit...hlgrenska Academy and Sahlgrenska University Hospi...restigious Proceedings of the National Academy of...n Swedish men doing military service who were born...d the results of both physical and IQ tests when t...

(Date:12/2/2009)...bacco product called moist snuff placed between l...e the tobacco industry to change manufacturing pra...heir study is published online in ACS, monthly jou... that this category of tobacco products contains s...r-causing substances. Called polycyclic aromatic h...

(Date:12/2/2009)..., Calif. and PALM HARBOR, Fla., Dec. 2 /PRNewswire...ion ("CIC") (OTC Bulletin Board: CICI), a leading ...iness process automation in the financial industry...re verification and Docubase Systems Inc. ("Docuba...Management (EDM) software provider announced today...

Breaking Biology News(10 mins):Young adults who exercise get higher IQ 2 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 2 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 3 CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions 4 Partnership to accelerate Trudeau Institute discoveries to patient care 8711 1 Partnership to accelerate Trudeau Institute discoveries to patient care 8711 2 Fountain View of Monroe Participates in Illegal Union Busting Campaign 47815 1 Fountain View of Monroe Participates in Illegal Union Busting Campaign 47815 2 Healthcarebluebook com 3A DC Area Consumers Must Stop Overpaying for Tests and Treatments 47811 1 Healthcarebluebook com 3A DC Area Consumers Must Stop Overpaying for Tests and Treatments 47811 2

[0] Young adults who exercise get higher IQ [0] Smokeless tobacco called 'moist snuff' is contaminated with harmful substances [0] CIC Teams with Docubase Systems to Deliver eSignature Enabled Document Management Solutions

... at the University of California, San Diego have i... evening components of the daily biological clock ...ch 13 issue of Science , solves a longstanding pu...hat control plant clocks and could provide a new w...l crops. , The finding is the first outcome of a ...

...ARCH 19 Ten prominent journalists from the United...selected for the fifth annual TempletonCambridge J...gurated in 2004, the fellowships include a program...Cambridge in England. The 2009 fellows were annou...Cambridge Fellowships, which are funded by the Joh...

...iz. March 18, 2009 Dr. Daniel Von Hoff, Physicia...Institute (TGen), has won an award recognizing his... who also is Chief Scientific Officer of TGen Clin...ill be recognized in the category of Health Care R...Business Magazine. Dr. Von Hoff was honored March...

Other Biology News:Missing piece of plant clock found 2 Fifth annual Templeton-Cambridge fellowships awarded to 10 noted journalists 2 Fifth annual Templeton-Cambridge fellowships awarded to 10 noted journalists 3 Fifth annual Templeton-Cambridge fellowships awarded to 10 noted journalists 4 TGen's Dr. Von Hoff wins award for cancer research 2

Missing piece of plant clock found Fifth annual Templeton-Cambridge fellowships awarded to 10 noted journalists TGen's Dr. Von Hoff wins award for cancer research

UCB Basophil Chip-IHC from 3H Biomedical AB

UCB CD4 T Cell Chip-IHC from 3H Biomedical AB

EPC Cell Chip-IHC from 3H Biomedical AB

MoDC Cell Chip-IHC from 3H Biomedical AB

Biology Products:

UCB Basophil Chip-IHC from 3H Biomedical AB UCB CD4 T Cell Chip-IHC from 3H Biomedical AB EPC Cell Chip-IHC from 3H Biomedical AB MoDC Cell Chip-IHC from 3H Biomedical AB

Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phas...( Central Texas man receives groundbrea...)